JP2006526644A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006526644A5 JP2006526644A5 JP2006515006A JP2006515006A JP2006526644A5 JP 2006526644 A5 JP2006526644 A5 JP 2006526644A5 JP 2006515006 A JP2006515006 A JP 2006515006A JP 2006515006 A JP2006515006 A JP 2006515006A JP 2006526644 A5 JP2006526644 A5 JP 2006526644A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- composition according
- aag
- enzyme inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000002532 enzyme inhibitor Substances 0.000 claims 13
- 229940125532 enzyme inhibitor Drugs 0.000 claims 13
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical group N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 12
- 229950007866 tanespimycin Drugs 0.000 claims 12
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 11
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical group N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 229940084651 iressa Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47490603P | 2003-05-30 | 2003-05-30 | |
| US10/856,696 US20050020557A1 (en) | 2003-05-30 | 2004-05-27 | Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors |
| PCT/US2004/016889 WO2005000213A2 (en) | 2003-05-30 | 2004-05-28 | Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006526644A JP2006526644A (ja) | 2006-11-24 |
| JP2006526644A5 true JP2006526644A5 (https=) | 2007-07-12 |
Family
ID=34083152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515006A Abandoned JP2006526644A (ja) | 2003-05-30 | 2004-05-28 | Ｈｓｐ−９０阻害剤を酵素インヒビターとのコンビネーションにおいて使用する疾患の治療方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20050020557A1 (https=) |
| EP (1) | EP1628623A4 (https=) |
| JP (1) | JP2006526644A (https=) |
| WO (1) | WO2005000213A2 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090197852A9 (en) * | 2001-08-06 | 2009-08-06 | Johnson Robert G Jr | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |
| US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20050020534A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| US20050026893A1 (en) * | 2003-05-30 | 2005-02-03 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
| US20050020556A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
| DK2238982T3 (da) * | 2003-06-27 | 2013-01-28 | Astellas Pharma Inc | Terapeutisk middel til blødt væv-sarcom |
| WO2005065681A1 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer |
| US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| WO2006055760A1 (en) * | 2004-11-18 | 2006-05-26 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| JP2008524246A (ja) * | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
| US7642253B2 (en) * | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EA200800321A1 (ru) * | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| JP2009504673A (ja) * | 2005-08-11 | 2009-02-05 | ノバルティス アクチエンゲゼルシャフト | ピリミジルアミノベンズアミド化合物であるタンパク質キナーゼ阻害剤および１７−ａａｇのようなｈｓｐ９０阻害剤を含む組合せ |
| WO2007094819A2 (en) | 2005-08-18 | 2007-08-23 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CA2636596A1 (en) * | 2005-11-04 | 2007-05-18 | James Pluda | Method of treating cancers with saha and pemetrexed |
| US20090042847A1 (en) * | 2005-11-23 | 2009-02-12 | Kosan Biosciences Incorporated | 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations |
| US7648976B2 (en) * | 2005-11-23 | 2010-01-19 | Bristol-Myers Squibb Company | 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations |
| WO2007084390A2 (en) * | 2006-01-13 | 2007-07-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2007139960A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
| CN101528037A (zh) * | 2006-11-03 | 2009-09-09 | 默克公司 | 使用saha和硼替佐米治疗多发性骨髓瘤的方法 |
| DE102007002715A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| EP2200931B1 (en) * | 2007-09-19 | 2017-06-07 | The Charles Stark Draper Laboratory, Inc. | Microfluidic structures with circular cross-section |
| US20090234332A1 (en) * | 2008-03-17 | 2009-09-17 | The Charles Stark Draper Laboratory, Inc | Artificial microvascular device and methods for manufacturing and using the same |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| EP2773345A1 (en) | 2011-11-02 | 2014-09-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| US9421315B2 (en) | 2012-09-05 | 2016-08-23 | The Charles Stark Draper Laboratory, Inc. | Compact hydraulic manifold structure for shear sensitive fluids |
| US9656212B2 (en) | 2013-01-08 | 2017-05-23 | The Charles Stark Draper Laboratory, Inc. | Compact hydraulic manifold structure for shear sensitive fluids |
| EP3107597B1 (en) | 2014-02-17 | 2018-12-05 | The Charles Stark Draper Laboratory, Inc. | Microfluidic manifold for shear sensitive fluids |
| KR20160015076A (ko) | 2014-07-30 | 2016-02-12 | 삼성전자주식회사 | c-Met 저해제의 효능 예측을 위한 바이오마커 Hsp90 |
| KR102259232B1 (ko) | 2014-08-25 | 2021-05-31 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| EP0706373B1 (en) * | 1992-03-23 | 2000-07-19 | Georgetown University | Liposome encapsulated taxol and a method of using the same |
| US5387584A (en) * | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
| AU6833994A (en) * | 1993-05-17 | 1994-12-12 | Liposome Company, Inc., The | Incorporation of taxol into liposomes and gels |
| US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| DE69735057T2 (de) * | 1996-03-12 | 2006-08-31 | PG-TXL Co., L.P., Houston | Wasserlösliche paclitaxel-prodrogen |
| US6682758B1 (en) * | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
| US6245759B1 (en) * | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6174875B1 (en) * | 1999-04-01 | 2001-01-16 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
| HRP20020349A2 (en) * | 1999-10-19 | 2004-02-29 | Merck & Co Inc | Tyrosine kinase inhibitors |
| US6313138B1 (en) * | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2002060430A1 (en) * | 2001-02-01 | 2002-08-08 | Cornell Research Foundation, Inc. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
| EP1373215B1 (en) * | 2001-03-30 | 2006-07-26 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Geldanamycin derivatives useful for treating cancer |
| WO2003013430A2 (en) * | 2001-08-06 | 2003-02-20 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
-
2004
- 2004-05-27 US US10/856,696 patent/US20050020557A1/en not_active Abandoned
- 2004-05-28 JP JP2006515006A patent/JP2006526644A/ja not_active Abandoned
- 2004-05-28 WO PCT/US2004/016889 patent/WO2005000213A2/en not_active Ceased
- 2004-05-28 EP EP04753673A patent/EP1628623A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006526644A5 (https=) | ||
| JP2024109585A5 (https=) | ||
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| CN109640981A (zh) | 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途 | |
| CN1440283A (zh) | 有机化合物的联合形式 | |
| WO2004073632A3 (en) | Rapid absorption selective 5-ht agonist formulations | |
| JP2007523049A5 (https=) | ||
| NO20092033L (no) | Nye forbindelser | |
| WO2004045579A3 (en) | Pharmaceutical compositions and dosage forms of thalidomide | |
| ATE543489T1 (de) | Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür | |
| WO2004037190A3 (en) | Modified release compositions of milnacipran | |
| AU2003210300A1 (en) | The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure | |
| NO20084065L (no) | Hurtig frigivelses paracetamol tabletter | |
| NO20060185L (no) | Anvendelse av isomalt (blanding av 1,6 GPS og 1,1 GPM) som prebiotikum blant annet for fremstilling av et legemiddel for behandling av tarmsykdommer | |
| WO2008008474A3 (en) | Compositions and methods for the treatment of chronic pain conditions | |
| JP5784274B2 (ja) | Ｈｄａｃ阻害剤と代謝拮抗剤の組み合わせ | |
| EP1633402A2 (en) | Pharmaceutical composition | |
| NO20074933L (no) | Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat | |
| EP2281561A3 (en) | Use of LCK inhibitors for treatment of immunologic diseases | |
| TW200624431A (en) | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| WO2007031887A3 (en) | Extended release pharmaceutical composition of metformin and a process for producing it | |
| JP2009518415A5 (https=) | ||
| WO2004112794A3 (en) | New pharmaceutical uses of staurosporine derivatives |